Navigation Links
Depomed To Present At Piper Jaffray 2013 Healthcare Conference
Date:12/2/2013

NEWARK, Calif., Dec. 2, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) today announced that it will be presenting at the Piper Jaffray 25th Annual Healthcare Conference at The New York Palace Hotel in New York City.

The presentation at the Piper conference is scheduled for 12:10 pm EST (9:10 am PST) on Tuesday, December 3, 2013.  The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com.  A recording of the webcast will be archived for 30 days on the company's website.

About Depomed

Depomed, Inc. is a specialty pharmaceutical company that commercializes products for pain and neurology related disorders. Gralise® (gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia. Zipsor® (diclofenac potassium) Liquid Filled Capsules is a non-steroidal anti-inflammatory drug indicated for relief of mild to moderate acute pain in adults. Lazanda® (fentanyl) Nasal Spray is an intranasal fentanyl drug used to manage breakthrough pain in adults (18 years of age or older) who are already routinely taking other opioid pain medicines around-the-clock for cancer pain. Gralise and other products and product candidates are formulated with Depomed's proven, proprietary Acuform® drug delivery technology. Additional information about Depomed may be found at www.depomed.com.

CONTACT: August J. Moretti  
Depomed, Inc. 650-462-5900
amoretti@depomed.com

 


'/>"/>
SOURCE Depomed, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Depomed Reports Third Quarter 2013 Financial Results
2. Depomed To Report Third Quarter Fiscal Year 2013 Financial Results On Tuesday, November 5, 2013
3. Depomed Sells Type 2 Diabetes Royalties And Milestones To PDL BioPharma For $240.5 Million
4. PDL BioPharma Acquires Portfolio of Diabetes Royalty Rights and Milestones from Depomed
5. Depomed Expands Geographic Scope of License Agreement with Merck for Extended Release Metformin Patents
6. Depomed Reports Second Quarter 2013 Financial Results
7. Depomed To Report Second Quarter Fiscal Year 2013 Financial Results On Wednesday, August 7, 2013
8. FDA Grants Priority Review To New Drug Application For MNK-795 Submitted By Depomed Licensee Mallinckrodt
9. Depomed Announces Appointment of Louis J. Lavigne, Jr. to Board of Directors
10. Depomed to Present at Wells Fargo Securities 2013 Healthcare Conference
11. Depomed To Present At Jefferies 2013 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Aug. 27, 2014 Ambit Biosciences (Nasdaq: AMBI ... drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, ... Care Conference to be held at The New York Palace ... September 3-4, 2014. Alan Fuhrman , Ambit,s ... lead drug candidate, quizartinib, at 1:10 p.m. ET on Wednesday, ...
(Date:8/27/2014)... -- After the February 2014 launch of their new ... medical practices and management companies, Prime Clinical is reporting ... "The feedback has been great," says Director of ... of demos and new sign-ups is a reflection of ... of software features." Prime Clinical developed ...
(Date:8/27/2014)... 27, 2014  Zimmer Holdings, Inc. (NYSE and SIX: ... it will be participating in the Morgan Stanley 2014 ... New York, New York , on Tuesday, ... CEO of Zimmer, will be presenting at 9:10 a.m. ... of Biomet, will join Mr. Dvorak for the Q&A ...
Breaking Medicine Technology:Ambit Announces Participation At Baird 2014 Health Care Conference 2Medical Software Company, Prime Clinical Systems, Sees Excellent Response to their Workers' Compensation Solutions 2Medical Software Company, Prime Clinical Systems, Sees Excellent Response to their Workers' Compensation Solutions 3
(Date:8/27/2014)... The American Brain Tumor Association ... 2014-2016 Basic Research Fellowships and 2014-2015 Discovery Grant Awards. ... is seeding the field with talented, bright young investigators ... the causes, effects, diagnosis and treatment of brain tumors. ... based on the potential to advance the understanding and ...
(Date:8/27/2014)... the onset of a cancer defense mechanism known ... Cancer Center are leveraging it in a new ... cell death rather than survival. The novel treatment ... referred to as the "Trash Man" due to ... autophagy. Results from preclinical experiments suggest this experimental ...
(Date:8/27/2014)... Cash House 's contributions to Horizons ... upkeep of the shelter including new initiatives and a wide ... the lives of each youth who walk through their door. ... for youth ages 16-25. Not only does Horizons operate as ... for the youth who come through their doors. Horizons has ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 IQ ... supplements, today announced its continued support of the Cystic ... Formulations participated in a fundraising campaign led by TigerFitness.com ... of IQ Formulations’ sales were donated to the respected ... to a TigerFitness.com fundraiser to support Isla, a young ...
(Date:8/27/2014)... BCC Research ( http://www.bccresearch.com ) reveals ... AND REGENERATIVE PRODUCTS , the global market for advanced ... by 2014-end to $42.2 billion by 2019, with a ... to 2019. New technologies and an increasingly older population ... market. , While there are many conventional and generally ...
Breaking Medicine News(10 mins):Health News:American Brain Tumor Association Awards New Research Grants to Best and Brightest Investigators 2Health News:American Brain Tumor Association Awards New Research Grants to Best and Brightest Investigators 3Health News:Promising new cancer therapy uses molecular 'Trash Man' to exploit a common cancer defense 2Health News:Cash House a Major Supporter of Horizons for Youth 2Health News:Cash House a Major Supporter of Horizons for Youth 3Health News:IQ Formulations Contributes Sizeable Donation to Cystic Fibrosis Foundation 2Health News:Global Market for Advanced Orthopedic Technology to Reach $42.2 Billion in 2019; Biotechnological Advancements Driving the Market 2Health News:Global Market for Advanced Orthopedic Technology to Reach $42.2 Billion in 2019; Biotechnological Advancements Driving the Market 3
... study report based on detainee interrogations finds that ... not involve physical pain—such as psychological// manipulation, deprivation, ... much mental distress and traumatic stress as physical ... torture encompass both physical and mental pain and ...
... that nearly four out of five hospitalized children receive ... adults//. The authors fear that treating children with off-label ... the magnitude of off-label use of drugs in children," ... specializing in infectious diseases at The Children’s Hospital of ...
... been a success, but continued commitment from the government is ... officials. ,The Immunization Plus Days (IPDs) initiative was ... (NPI) ¯ a government initiative with support from UNICEF and ... 18 northern regions still affected by the virus. ...
... Scientists have developed a test for the early diagnosis of lung ... and off in cells// lining the airways leading to the lungs ... effective. ,Lung cancer is the most deadly form of ... men and the third most common in women. In 2002 about ...
... University researchers have released results of a study showing ... intake//, higher body weight, a decrease in calcium and ... ,The report also noted that studies funded ... show detrimental effects from soft drinks than studies that ...
... the accurate amount of fat in a human body, according// to ... for measuring the amount of fat in a person's body. It ... of their height. ,Generally, a BMI of 25 or ... A person with a higher BMI is thought to be at ...
Cached Medicine News:Health News:All Forms of Ill Treatment Cause Post Traumatic Stress Disorder-PTSD 2Health News:All Forms of Ill Treatment Cause Post Traumatic Stress Disorder-PTSD 3Health News:Prescribing Off Label Drugs for Children may Be Hazardous 2Health News:Prescribing Off Label Drugs for Children may Be Hazardous 3Health News:Nigerian Programme Increases Polio Immunisation 2Health News:Gene Cell Test may Aid Early Lung Cancer Diagnosis 2Health News:Yale Researchers Weigh the Science on Soft Drinks and Health 2
For the quantitative determination of Gamma Glutamyltransferase in serum or plasma...
The CK method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of creatine kinase activity in serum and plasma...
The XCHO method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of cholesterol in serum and plasma....
For the quantitative in vitro determination of Cholesterol in serum and plasma....
Medicine Products: